Novartis AG ADR (NVS)vsScinai Immunotherapeutics Ltd (SCNI)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
SCNI
Scinai Immunotherapeutics Ltd
$0.74
+3.67%
HEALTHCARE · Cap: $2.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4315537% more annual revenue ($56.58B vs $1.31M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SCNI
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+52.8%
Fair Value
$1.59
Current Price
$0.74
$0.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 30.6% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -91.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SCNI
The strongest argument for SCNI centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 1.99 — expect wider price swings.
SCNI is growing revenue faster at 30.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 48/100), backed by strong 23.9% margins. SCNI offers better value entry with a 52.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?